AsianScientist (Jun. 28, 2012) – Eisai Co. Ltd. announced today that it has received regulatory approval by the Ministry of Health and Social Development of the Russian Federation for the sale of its antiepileptic drug, Zonegran (zonisamide) there.
Zonegran is the first product by Eisai that has been approved for use in Russia. It is approved as an adjunctive therapy in the treatment of adult epilepsy patients with partial seizures.
Zonegran was originally created by Dainippon Pharmaceutical Co., Ltd. (currently Dainippon Sumitomo Pharma Co., Ltd.), for which Eisai holds development, manufacturing, and marketing rights in Russia as well as in Europe, the United States, and Asia.
Eisai has a representative office in Moscow that is overseen by its U.K. subsidiary Eisai Europe Limited. The company has already submitted marketing authorization applications for three other products: anticancer agent Halaven(R) (eribulin mesylate) and AMPA-type glutamate receptor antagonist FYCOMPA(R) (perampanel), and antiepileptic agent Exalief(R) (under license from BIAL-Portela & Ca S.A.).
According to its press report, Eisai hopes to enter the world’s top 20 largest pharmaceuticals markets by fiscal 2015 as part of its mid-term strategic plan, Hayabusa.
——
Source: Eisai.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
